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Patients with psoriasis are frequently complicated with autoimmune bullous diseases,
especially, pemphigoid diseases. It has been known that one-third cases of anti-laminin
gamma1 pemphigoid, formerly anti-p200 pemphigoid, are associated with psoriasis
whereas bullous pemphigoid is the most frequently associated bullous disease in
psoriasis cases regardless of the lack of detectable levels of the accompanying anti-
laminin gamma1 autoantibodies. Despite several suggestions, however, the definitive
reason of the striking association of psoriasis and these autoimmune bullous diseases
remains elusive. In this review, we look over the epidemiological evidence of the
association of psoriasis and autoimmune bullous diseases and the information of
genetic susceptibilities of each disease, and discuss the possible mechanisms of their
complication with reference to the recent understandings of each pathogenesis.
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INTRODUCTION
Autoimmune bullous diseases, as well as psoriasis, are skin disorders affecting the epidermis. In
both diseases, immune reactions target the epidermis, and induce the development of the skin
lesions following the failures in epithelial cell contacts or the defects in epithelial cell proliferation
and differentiation. There is remarkable progress in the understandings of their pathogenesis
in these decades, respectively. Nevertheless, (1) what triggers the pathogenic immune reactions,
(2) which cells by which molecules respond to the internal or external changes and direct the
subsequent immune reactions, and (3) which step is critical for the decision of the immune type,
have not yet been fully elucidated.
Physicians and dermatologists have long time been aware that psoriasis patients are frequently
complicated with autoimmune bullous diseases. Indeed, epidemiological evidence indicates that
the incidence of some pemphigoid diseases in psoriasis patients is significantly higher than that in
the control individuals without psoriasis. Moreover, recent investigations have suggested that there
are in part similarities and shared players in their pathogenesis.
In this review, first we look over the epidemiological evidence of the association of psoriasis
and autoimmune bullous diseases. Second, we compare their genetic susceptibilities. And third, we
discuss the possible mechanisms of their association with reference to the current understandings
on each pathogenesis.
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EPIDEMIOLOGICAL EVIDENCE
Psoriasis and Pemphigus
Most reported cases of pemphigus developed in psoriasis patients
were pemphigus foliaceus including pemphigus erythematosus.
A case series of 145 patients with concomitant psoriasis and
autoimmune blistering diseases from Japan reported that all four
(2.8%) pemphigus cases with psoriasis were pemphigus foliaceus
(124). The first case-control study of 51,800 psoriasis patients
from Taiwan demonstrated the significantly higher prevalence
rate of pemphigus in the patients than that in the control subjects
(odds ratio (OR), 41.8; 95% confidence interval (CI), 12.4–140.9;
P < 0.0001) (125).
There is another study evaluating their association in an
inverse direction: a case-control study of 1985 pemphigus
patients from Israel demonstrated that the prevalence rate of
psoriasis in pemphigus patients was also higher than that in the
controls (OR, 2.84; 95% CI, 2.09–3.85, P < 0.001) (126).
Psoriasis and Pemphigoid Diseases
Including Epidermolysis Bullosa Acquisita
Complication of psoriasis cases with pemphigoid diseases are
much more commonly experienced than those with pemphigus
whereas the number of the report of the psoriasis cases
with pemphigoid is only about three times as many as those
with pemphigus (Figure 1). Indeed, in the case series of 145
patients with psoriasis and autoimmune blistering diseases
from Japan, almost all the cases are complicated with bullous
pemphigoid (63%), anti-laminin γ1 pemphigoid (formerly anti-
p200 pemphigoid) (37%), or their combination (8%) (Figure 2).
Psoriasis including pustular psoriasis precedes the development
of pemphigoid in most cases. Of note, 111 (78.7%) cases
had no history of any phototherapies in this case series
(124).
FIGURE 1 | Publication of the report of cases with association of psoriasis and bullous diseases until the end of 2017. All the publications were searched in PubMed
database, and case reports and case series were selected manually with exclusion of redundancy. Cases with coexistence of two or more autoimmune blistering
diseases were counted in each category: (psoriasis[tiab] AND pemphigoid[tiab]) for pemphigoid diseases; (psoriasis[tiab] AND pemphigus[tiab] NOT pemphigoid[tiab])
for pemphigus; psoriasis[tiab] AND (epidermolysis bullosa acquisita[tiab]) for epidermolysis bullosa acquisita; psoriasis AND (epidermolysis bullosa hereditaria OR
epidermolysis bullosa simplex OR junctional epidermolysis bullosa OR dystrophic epidermolysis bullosa OR kindler’s syndrome OR kindler syndrome) for epidermolysis
bullosa hereditaria; psoriasis[tiab] AND (hailey-hailey OR familial pemphigus OR familial benign chronic pemphigus) for Hailey-Hailey disease. References are as
follows. Pemphigus (24): 1990 or earlier (5) (1–5); 1991–2000 (5) (6–10); 2001–2010 (6) (11–16); 2011 or later (8) (17–25). Pemphigoid (84): 1980 or earlier (7) (26–32);
1981–1990 (16) (3, 33–47); 1991–2000 (10) (48–57); 2001–2010 (21) (58–78); 2011 or later (30) (79–109). Epidermolysis bullosa acquisita (7) (51, 110–115).
Epidermolysis bullosa hereditaria (1) (116). Hailey-Hailey disease (7) (117–123).
The case-control study of 51,800 psoriasis patients from
Taiwan also demonstrated the higher prevalence rate of
pemphigoid in the patients than that in the control subjects (OR,
14.8; 95% CI, 5.00–43.50, P < 0.0001) (125).
Inversely, early case-controlled study has shown that 7 out
of 62 (11%) pemphigoid cases are complicated with psoriasis
and the prevalence was significantly higher than expected in
the controls (P < 0.01) (40). Following studies also confirmed
that psoriasis cases are significantly associated with bullous
pemphigoid: A study of 3,485 bullous pemphigoid cases from
Taiwan (OR 2.02; 95% CI 1.54–2.66, P < 0.003) (127), and
another of 287 bullous pemphigoid cases from Israel (OR 4.39;
95% CI 2.17–8.92, P < 0.0001) (128), respectively.
Anti-laminin γ1 pemphigoid is originally reported as
pemphigoid developed in psoriasis patients with circulating
autoantibodies against unknown autoantigen. Around one-third
of the following cases have also been associated with psoriasis
(129).
There are only a few reported cases of psoriasis associated
with other pemphigoid diseases. The case series of 145 patients
with psoriasis and autoimmune blistering diseases from Japan
included three cases with linear IgA bullous dermatosis and
two cases with epidermolysis bullosa acquisita (124). There are
few independent reports of a case with epidermolysis bullosa
acquisita (51, 112), or with anti-laminin 332 mucous membrane
pemphigoid (109).
Psoriasis and Other Blistering Diseases
Intriguingly, as far as we looked up, there is no reported
case of psoriasis in any type of epidermolysis bullosa: simplex,
junctional, or dystrophic type, except for one case report of
the dystrophic type without confirmation by DNA sequencing
analysis (116). There are seven reports of a case with psoriasis
in Hailey-Hailey disease since the first reported case (117).
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FIGURE 2 | Component of pemphigoid diseases associated with psoriasis
(124).
SUSCEPTIBILITIES OF PSORIASIS AND
BULLOUS DISEASES
HLA
No shared susceptibility human leukocyte antigen (HLA) alleles
have been reported between psoriasis and bullous diseases that
can be associated with psoriasis: HLA-Cw∗0602 allele has been
identified in psoriasis susceptibility 1 (PSORS1), a major psoriasis
susceptibility locus (130). On the other hand, HLA-DRB1
alleles, such as DRB1*1401, DRB1*0402, and DRB1*08 alleles
are associated with pemphigus vulgaris (131). HLA-DQB1∗0301
allele has been identified as a susceptibility gene for bullous
pemphigoid. Epidermolysis bullosa acquisita is associated with
DRB1∗15:03 allele (132).
Other Susceptibility Genes
Studies for single nucleotide polymorphisms have been defined
several psoriasis susceptibility genes (130, 133) (Table 1) whereas
it has been challenging to identify the susceptibility genes
of pemphigus or pemphigoid diseases and there is much
less information about their susceptibility genes. As for two
major bullous diseases that can be associated with psoriasis,
following genes are suggested to be associated with the disease
susceptibility:, IL1B (135), CD16 (136), ATP8 (137), and CYP2D6
(138) in bullous pemphigoid; and CD40L, CD40, BLYS (139),
CTLA4 (140), and CD59 (141) in pemphigus foliaceus. However,
they are not included in the major psoriasis susceptibility
genes except for the risk loci at IL1B in late onset psoriasis
(142). Susceptible SNPs in mucous membrane pemphigoid were
recently reported (143) whereas mucous membrane pemphigoid
rarely accompanied with psoriasis.
Transcriptomic Studies
Whereas transcriptomic analyses are preferentially demonstrated
to investigate the pathogenesis of psoriasis, it is not in
the case of autoimmune bullous diseases. The increased
expression levels of CD1D (4.0) and LILRB2 (4.7) were
reported in pemphigus foliaceus (144), neither of them were
included in the upregulated genes in psoriasis lesions (134)
(Table 2).
Consequently, these results suggest that the complication
of psoriasis with bullous pemphigoid or pemphigus
foliaceus are not attributed to the shared susceptibility.
Therefore, it would be more reasonable to consider that
the epigenetic events in psoriasis lesions give rise to the
increased rate of the complication with autoimmune bullous
diseases.
POTENTIAL MECHANISMS OF THE
ASSOCIATION OF PSORIASIS AND
PEMPHIGOID DISEASES
Local Inflammation
Psoriasis plaques are the frequently affected sites for the blister
formation of associated autoimmune bullous diseases, such
as bullous pemphigoid (58), anti-laminin γ1 pemphigoid
(49), and pemphigus foliaceus (7). It would be reasonable to
consider that epigenetic changes altered by psoriasis lesion
may trigger or accelerate autoreactive response to specific
antigens resulting in autoantibody production, blistering
formation, and further positive loop of organ-specific
autoimmunity (145). Whereas detailed speculations in this
context are described below, it is of not that local inflammation
exacerbates cutaneous manifestations in a murine autoimmune
pemphigus model (146), suggesting effective recruitment of
autoantibodies into psoriasis lesions and further autoimmune
loop.
Th17
There are much more psoriasis cases complicated with bullous
pemphigoid than those with pemphigus. We have demonstrated
that the percentages of interleukin (IL)-17+ cells in CD4+ cells
in the lesional skin from bullous pemphigoid are significantly
higher than those in the lesional skin from pemphigus foliaceus,
and that the serum levels of IL-17 in patients with bullous
pemphigoid is higher than those in healthy controls (147).
Although IL-17 from T helper type 17 (Th17) cells have
an essential role in pathogenesis of psoriasis, it does not
explain the common order of the disease development: bullous
pemphigoid following psoriasis despite the existence of a
rare, inverse case: psoriasis following bullous pemphigoid (77).
However, one may speculate that pathological events around
the epidermis shared between psoriasis and bullous pemphigoid
is related to the activation of Th17 in these diseases, and
incidental switch of the immune response from Th1 to Th2
induce the production of the IgG autoantibodies resulting
the complication of psoriasis with bullous pemphigoid (77)
(Figure 3). Because, animal studies have demonstrated that
single helper T cell clone specific for desmoglein 3 is sufficient
to recapitulate autoimmune blister formation whereas the
Th17-deviated T cell clone specific for desmoglein 3 induces
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TABLE 1 | SNPs in psoriasis and the related bullous diseases (130, 133).
Disease Category Symbols
Psoriasis HLA HLA-C*12:03, HLA-B, HLA-A, HLA-DQA1
MHC class-I processing ERAP1
NF-κB signaling REL, TNIP1, NFKBIA, CARD14
IFN signaling IL28RA, TYK2
T-cell regulation RUNX3, IL13, TAGAP, ETS1, MBD2, PTPN22
Antiviral signaling IFIH1, DDX58, RNF114
IL-23/IL-17 axis TNFAIP3, IL23R, IL12B, TRAF3IP2, IL23A, STAT3
Th2 IL4, IL13
Late cornified envelope LCE3B, LCE3C, LCE3D
Ubiquitin pathway ZNF313
Unknown CDKAL1
Bullous pemphigoid IL1B, CD16, ATP8, CYP2D6
multicolumn1lPemphigus foliaceus CD40L, CD40, BLYS, CTLA4, CD59
TABLE 2 | Top 25 upregulated genes in the psoriasis lesions relative to the non-lesional skin (134).
# Symbol Description Fold change
1 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 661
2 S100A12 S100 calcium binding protein A12 328
3 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) 309
4 S100A7A S100 calcium binding protein A7A 260
5 SPRR2C small proline-rich protein 2C (pseudogene) 167
6 DEFB4A defensin, beta 4A 138
7 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 89
8 PI3 peptidase inhibitor 3, skin-derived 80
9 IL8 interleukin 8 66
10 TMPRSS11D transmembrane protease, serine 11D 63
11 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 62
12 S100A9 S100 calcium binding protein A9 60
13 OASL 29-59-oligoadenylate synthetase-like 56
14 ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide 54
15 LCN2 lipocalin 2 53
16 RHCG Rh family, C glycoprotein 52
17 IGFL1 IGF-like family member 1 48
18 KYNU kynureninase (L-kynurenine hydrolase) 48
19 IL1F9 interleukin 1 family, member 9 43
20 KLK6 kallikrein-related peptidase 6 43
21 LTF lactotransferrin 36
22 CCL20 chemokine (C-C motif) ligand 20 35
23 C10orf99 chromosome 10 open reading frame 99 34
24 HPSE heparanase 33
25 ADAMDEC1 ADAM-like, decysin 1 33
psoriasiform dermatitis (148, 149). Occasional production of
autoantibodies against BP180 and desmogleins in lichen planus
cases has been reported regardless of accompanying blister
formation, probably because of the consequence of interface
dermatitis, suggesting Th1/Th2 dichotomy among lichen planus
vs. pemphigus or pemphigoid diseases (150). In psoriasis,
however, production of neither autoantibodies against BP180
nor desmogleins, but α6 integrin (151), in psoriasis has been
reported without complication with blistering diseases. It is
therefore unlikely that psoriasis and bullous pemphigoid or
pemphigus diseases are sharing their primary effector memory
T cells.
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FIGURE 3 | A mechanistic model to produce autoantibodies in psoriasis. Can
switch from the Th1/Th17-dominant to Th2/Th17-dominant state be involved?.
Neutrophils and MMP
Keratinocytes in both psoriasis and bullous pemphigoid produce
neutrophil chemoattractants, such as IL-8, and infiltration of
neutrophil is a common histologic feature in these diseases
(130, 131). Consequently, neutrophils release a series of
metalloproteases, and it might be related to the substantial
degradation of matrix proteins and the subsequent exposure
of the antigenic epitopes from matrix autoantigens composing
the dermal-epidermal junction. Specifically, a disintegrin and
metalloprotease (ADAM) 9, ADAM10, and ADAM17/ tumor
necrosis factor-alpha converting enzyme (TACE) degrade
BP180/type XVII collagen (152), which is a major autoantigen in
bullous pemphigoid while matrix metalloprotease (MMP) 2, 7, 8,
12, 14, 15, and 19 degrades laminins (153), of which trimers are
targeted in anti-laminin γ1 pemphigoid (154) and anti-laminin
332 mucous membrane pemphigoid (155).
Laminins
One may be tempted by the following idea: very high
prevalence of psoriasis in anti-laminin γ1 pemphigoid can be
explained by a positive loop of laminin degradation in psoriasis
(129). In psoriasis, as well as in trauma or staphylococcal
infections, degradation of laminin is accelerated through the
increased expression levels of α5β1 integrin, fibronectin, and
plasminogen activators (156). The laminin degradation is also
stimulated by MMP9 released from neutrophils. Furthermore,
laminin fragments stimulate the MMP9 expression. This laminin
degradation loop may be contributed to decrease the threshold
of spontaneous production of autoantibodies against laminin γ1
in the development of anti-laminin γ1 pemphigoid in psoriasis
patients.
Senescence
The median age of the development of bullous pemphigoid is
around 80 years of age. Cell cycle and turnover of the epidermal
keratinocytes are extremely accelerated in psoriasis whereas
keratinocytes in psoriasis are not immortalized like carcinoma
cells. Therefore, it is a plausible idea that the extracellular matrix
in psoriatic skin simulates the senescent extracellular matrix
and contribute to the development of bullous pemphigoid if
the development of bullous pemphigoid is triggered by the
senescence of the extracellular matrix produced by senescent
keratinocytes. The shortened telomere lengths in psoriasis have
not yet determined in keratinocytes or dermal fibroblasts, but in
lymphocytes (157). In terms of senescence, type XVII collagen
(BP180) changes its distribution (158) and the protein amount
due to proteolysis (159) by aging. Despite several suggestions,
however, the definitive reason of the predilection of bullous
pemphigoid in an extremely old age remains to be elucidated.
CONCLUDING REMARKS
Epidemiological studies have confirmed that psoriasis is highly
complicated by the subsequent development of autoimmune
bullous diseases. The order of the disease development
and the lack of shared susceptibility genes ask whether
epigenetic events and molecular circumstances in psoriasis
lesions raise the susceptibility to the organ-specific autoimmunity
in the skin. The high prevalence of bullous pemphigoid
and anti-laminin γ1 pemphigoid in patients with psoriasis
promotes following investigations on the pathogenesis of
each disease, especially about their unique types of immune
responses, as well as the involvement of the degradation
and senescence of extracellular proteins around the dermal-
epidermal junctions.
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